Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Apr. 30, 2016 | Jun. 17, 2016 | |
Document And Entity Information | ||
Entity Registrant Name | SCIVANTA MEDICAL CORP | |
Entity Central Index Key | 1,093,285 | |
Document Type | 10-Q | |
Document Period End Date | Apr. 30, 2016 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --10-31 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 20,805,685 | |
Trading Symbol | SCVM | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2,016 |
Balance Sheets (Unaudited)
Balance Sheets (Unaudited) - USD ($) | Apr. 30, 2016 | Oct. 31, 2015 |
Current assets: | ||
Cash | $ 38,982 | $ 21,658 |
Prepaid expenses | 5,428 | 6,969 |
Total current assets and total assets | 44,410 | 28,627 |
Current liabilities: | ||
Accounts payable | $ 116,709 | 102,086 |
Accounts payable - related party | 369,479 | |
Accrued expenses | $ 38,401 | 119,046 |
Convertible debentures | 225,000 | 694,791 |
Total current liabilities | $ 380,110 | 1,285,402 |
Note payable | 105,000 | |
Total liabilities | $ 380,110 | $ 1,390,402 |
Commitments | ||
Stockholders’ deficiency: | ||
Preferred stock, $.001 par value; 20,000,000 shares authorized; no shares issued | ||
Common stock, $.001 par value; 500,000,000 shares authorized; 20,805,685 and 6,359,055 shares issued and outstanding, respectively | $ 20,806 | $ 6,359 |
Additional paid-in capital | 24,223,708 | 23,080,594 |
Accumulated deficit | (24,580,214) | (24,448,728) |
Total stockholders’ deficiency | (335,700) | (1,361,775) |
Total liabilities and stockholders’ deficiency | $ 44,410 | $ 28,627 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - $ / shares | Apr. 30, 2016 | Oct. 31, 2015 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ .001 | $ .001 |
Preferred stock, shares authorized | 20,000,000 | 20,000,000 |
Preferred stock, shares issued | ||
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 500,000,000 | 500,000,000 |
Common stock, shares issued | 20,805,685 | 6,359,055 |
Common stock, shares outstanding | 20,805,685 | 6,359,055 |
Statements of Operations (Unaud
Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Apr. 30, 2016 | Apr. 30, 2015 | Apr. 30, 2016 | Apr. 30, 2015 | |
Income Statement [Abstract] | ||||
Revenue | ||||
Operating expenses: | ||||
General and administrative | $ 62,367 | $ 59,848 | $ 151,125 | $ 114,150 |
Gain on settlement of note payable | (105,000) | |||
Loss from operations | $ (62,367) | $ (59,848) | (46,125) | $ (114,150) |
Interest expense | (18,301) | $ (17,920) | (37,104) | $ (37,426) |
Loss on inducement of convertible debentures | (48,257) | (48,257) | ||
Net loss | $ (128,925) | $ (77,768) | $ (131,486) | $ (151,576) |
Net loss per common share, basic and diluted | $ (0.01) | $ (0.01) | $ (0.02) | $ (0.02) |
Weighted average number of common shares outstanding, basic and diluted | 8,992,736 | 6,359,055 | 7,661,425 | 6,359,055 |
Statements of Cash Flows (Unaud
Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Apr. 30, 2016 | Apr. 30, 2015 | |
Cash flows from operating activities: | ||
Net loss | $ (131,486) | $ (151,576) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Gain on settlement of note payable | (105,000) | |
Accretion of interest on convertible debentures | 8,713 | $ 9,343 |
Loss on inducement of convertible debentures | 48,257 | |
Changes in operating assets and liabilities: | ||
Prepaid expenses | 1,541 | $ 1,319 |
Accounts payable | 14,623 | (3,257) |
Accounts payable - related party | 87,285 | 71,282 |
Accrued expenses | 43,391 | 23,584 |
Net cash used in operating activities | (32,676) | (49,305) |
Cash flows from financing activities: | ||
Proceeds from issuance of convertible debenture | 50,000 | 50,000 |
Increase in cash | 17,324 | 695 |
Cash - beginning of period | 21,658 | 26,114 |
Cash – end of period | 38,982 | 26,809 |
Supplemental disclosure of cash flow information: | ||
Cash paid for income taxes | 500 | 500 |
Noncash financing activities: | ||
Discount recorded in connection with issuance of convertible debenture | 3,504 | $ 7,610 |
Issuance of 7,419,490 shares of common stock as payment of principal and interest due on convertible debentures | 649,036 | |
Issuance of 7,027,140 shares of common stock as settlement of accounts payable – related party | $ 456,764 |
Statements of Cash Flows (Paren
Statements of Cash Flows (Parenthetical) - shares | 6 Months Ended | |
Apr. 30, 2016 | Apr. 30, 2015 | |
Statement of Cash Flows [Abstract] | ||
Common stock shares issued as payment for principal and interest due on convertible debentures | 7,419,490 | |
Common stock shares issued as setttlement of certain accounts payable related party | 7,027,140 |
Basis of Presentation
Basis of Presentation | 6 Months Ended |
Apr. 30, 2016 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation | 1. Basis of Presentation The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant recurring operating losses and negative cash flows from operations. The Company had a working capital deficiency of $335,700 and an accumulated deficit of $24,580,214 as of April 30, 2016. The Company has not made the $25,000 principal payment due on a convertible debenture and, as a result, that obligation can be placed in default by the holder. The Company also has no lending relationships with commercial banks and is dependent on the completion of a financing involving the private placement of its securities in order to continue operations. These factors raise substantial doubt about the Companys ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. On November 10, 2006, the Company licensed the exclusive world-wide rights to develop, manufacture and distribute certain proprietary technologies known as the Scivanta Cardiac Monitoring System (the SCMS), a minimally invasive two-balloon esophageal catheter system used to monitor cardiac performance. On January 22, 2016, the Company and the Licensor (as hereinafter defined) terminated the SCMS license agreement and, as a result, all property related to the SCMS held by the Company, including intellectual property, was assigned and returned to the Licensor (see Note 2). The Companys strategy for business development is focused on the acquisition, through licensing or purchasing, of medical devices, pharmaceuticals and other proprietary technologies, patented products or services. Any such acquisitions will be contingent upon the Companys ability to secure the financing required to fund such acquisitions. The Company continues to seek equity and/or debt investors and from time to time engages placement agents to assist the Company in this initiative. Effective November 1, 2011, each of the Companys officers agreed to waive the annual base salary due to them and each of the Companys directors agreed to waive the annual retainer and meeting fees due to them until the Company is able to raise sufficient capital that would provide the Company with the ability to pay cash compensation to its officers and directors. The Company has also paid certain obligations with shares of its common stock and has deferred certain other vendor payments until the Company secures sufficient additional debt or equity financing. While the Company is pursuing the opportunities and actions described above, there can be no assurance that it will be successful in its efforts. If the Company is unable to secure additional capital, it will explore other strategic alternatives, including, but not limited to, the sale of the Company. Any additional equity financing may result in substantial dilution to our stockholders. |
Amended and Restated SCMS Licen
Amended and Restated SCMS License Agreement | 6 Months Ended |
Apr. 30, 2016 | |
Amended And Restated Scms License Agreement | |
Amended and Restated SCMS License Agreement | 2. Amended and Restated SCMS License Agreement On February 14, 2011, the Company entered into an Amended and Restated Technology License Agreement with The Research Foundation of State University of New York, for and on behalf of the University at Buffalo (the Foundation), Donald D. Hickey, M.D. (Hickey) and Clas E. Lundgren (Lundgren). The Foundation, Hickey and Lundgren shall be collectively referred to herein as the Licensor. The Amended and Restated Technology License Agreement, as further amended on March 14, 2013, is referred to herein as the License Agreement. Pursuant to the License Agreement, the Licensor granted the Company the exclusive world-wide rights to develop, manufacture and distribute certain proprietary technologies known as the SCMS. A cash payment of $105,000 was payable by the Company to Hickey as follows: (a) $50,000 was due to Hickey on or before a date that is thirty (30) days after the closing of any single financing by the Company of at least $3,000,000 or any series of financings by the Company within a six (6) month period totaling at least $3,000,000; and (b) $55,000 was due to Hickey on or before the date that is thirty (30) days after the first commercial sale of a product utilizing the licensed technology (see Note 4). On January 22, 2016, the Company and the Licensor entered into an agreement to terminate the License Agreement (the License Termination Agreement). The Company and the Licensor released each other from any and all claims and liabilities related to the License Agreement, including the $105,000 payment due to Hickey (see Note 4). In addition, pursuant to the License Termination Agreement, the Company assigned all intellectual property related to the SCMS to the Licensor and returned all property in its possession related to the SCMS to the Licensor. |
Related Party Transactions
Related Party Transactions | 6 Months Ended |
Apr. 30, 2016 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 3. Related Party Transactions David R. LaVance, the Companys Chairman, President and Chief Executive Officer, and Thomas S. Gifford, the Companys Executive Vice President, Chief Financial Officer and Secretary, are principals of Century Capital Associates LLC (Century Capital). Effective February 1, 2007, the Company and Century Capital entered into a sublease agreement (the Sublease Agreement) pursuant to which the Company rents office space approximating 2,000 square feet inside Century Capitals existing offices. In addition, the Company rents office furniture and other equipment from Century Capital. This agreement has a month to month term that requires sixty days written notice to terminate and a monthly rental fee of $5,000. The Company is responsible for all operating costs associated with the office space, including utilities, maintenance and property taxes. During the three and six months ended April 30, 2016, the Company was billed $16,281 and $38,235, respectively, pursuant to the terms of the Sublease Agreement. On April 30, 2016, the Company paid $135,000 of rent and $36,899 of expenses due under the Sublease Agreement for the period commencing February 1, 2014 through April 30, 2016 and $284,865 of other expenses due to Century Capital for the period commencing September 1, 2013 through April 30, 2016 through the issuance of 7,027,140 shares of the Companys common stock (see Note 8). During the three and six months ended April 30, 2015, the Company was billed $17,073 and $34,693, respectively, pursuant to the terms of the Sublease Agreement. |
Note Payable
Note Payable | 6 Months Ended |
Apr. 30, 2016 | |
Debt Disclosure [Abstract] | |
Note Payable | 4. Note Payable Pursuant to the License Agreement, a cash payment of $105,000 was payable to Hickey. Pursuant to the License Termination Agreement, the Licensor released the Company from any obligation regarding payment of the $105,000 to Hickey (see Note 2). Accordingly, for the six months ended April 30, 2016, the Company recorded a $105,000 gain on the settlement of the note payable. |
Convertible Debentures
Convertible Debentures | 6 Months Ended |
Apr. 30, 2016 | |
Debt Disclosure [Abstract] | |
Convertible Debentures | 5. Convertible Debentures February 2007 Convertible Debentures On February 8, 2007, the Company issued 8% convertible debentures, dated February 1, 2007, in the aggregate principal amount of $250,000 to individual investors (the February 2007 Debentures). The February 2007 Debentures bear interest at a rate of 8% per annum and originally had a three year term, maturing on January 31, 2010, which was initially extended to January 31, 2012. On January 11, 2012, the Company issued 50,000 shares of common stock as full payment of $50,000 of outstanding principal on certain February 2007 Debentures. On March 31, 2016, the Company issued 856,934 shares of common stock as full payment of $175,000 of outstanding principal due on the February 2007 Debentures and $34,302 of accrued and unpaid interest for the period commencing February 1, 2014 through March 31, 2016 (January 31, 2016 for the February 2007 Debenture that was not converted into shares of common stock on March 31, 2016). The number of shares issued as payment of the principal due was based on the conversion price as defined in the February 2007 Debentures and the number of shares issued as payment of the interest due was calculated based on the market price of the Companys common stock as defined in the February 2007 Debentures (see Note 8). As of April 30, 2016, the remaining outstanding principal amount of the February 2007 Debentures was $25,000. The Company has not made payment on the outstanding balance of the remaining February 2007 Debenture and, as a result, such obligation can be placed in default by the holder. For the three and six months ended April 30, 2016, the Company recorded a total of $2,793 and $6,826, respectively, of interest expense related to the February 2007 Debentures. For the three and six months ended April 30, 2015, the Company recorded a total of $3,902 and $7,935, respectively, of interest expense related to the February 2007 Debentures. As of April 30, 2016, $493 of interest due on the February 2007 Debentures was accrued and is included as a component of accrued expenses. As of April 30, 2016, the Company recorded the $25,000 of outstanding principal due on the remaining February 2007 Debenture as a component of current convertible debentures. May 2011 Convertible Debenture On May 20, 2011, the Company issued an 8% convertible debenture in the principal amount of $100,000 to an institutional investor (the May 2011 Debenture). The May 2011 Debenture bears interest at a rate of 8% per annum and originally had a three year term maturing on May 20, 2014 that was initially extended to May 20, 2015. Effective April 1, 2016, the holder agreed to a new maturity date of March 31, 2017. On March 31, 2016, the Company issued 128,205 shares of common stock to the May 2011 Debenture holder in satisfaction of $16,000 of interest due for the period commencing May 20, 2013 through May 19, 2015. The number of shares issued as payment of the interest due was calculated based on the market price of the Companys common stock as defined in the May 2011 Debenture (see Note 8). For the three and six months ended April 30, 2016, the Company recorded a total of $1,973 and $3,990 of interest expense related to the May 2011 Debenture. For the three and six months ended April 30, 2015, the Company recorded a total of $1,951 and $3,968 of interest expense related to the May 2011 Debenture. As of April 30, 2016, $7,614 of interest due on the May 2011 Debenture was accrued and is included as a component of accrued expenses. As of April 30, 2016, the Company recorded the $100,000 of outstanding principal due on the May 2011 Debenture as a component of current convertible debentures. August 2012 Convertible Debenture On August 15, 2012, the Company issued an 8% convertible debenture in the principal amount of $100,000 to an institutional investor (the August 2012 Debenture). The August 2012 Debenture originally had a three year term maturing on August 15, 2015 and bears interest at a rate of 8% per annum. Effective April 1, 2016, the holder agreed to a new maturity date of March 31, 2017. On March 31, 2016, the Company issued 161,538 shares of common stock to the August 2012 Debenture holder in satisfaction of $16,000 of interest due for the period commencing August 15, 2013 through August 14, 2015. The number of shares issued as payment of the interest due was calculated based on the market price of the Companys common stock as defined in the August 2012 Debenture (see Note 8). For the three and six months ended April 30, 2016, the Company recorded a total of $1,973 and $3,990 of interest expense related to the August 2012 Debenture. For the three and six months ended April 30, 2015, the Company recorded a total of $1,951 and $3,968 of interest expense related to the August 2012 Debenture. As of April 30, 2016, $5,794 of interest due on the August 2012 Debenture was accrued and is included as a component of accrued expenses. As of April 30, 2016, the Company recorded the $100,000 of outstanding principal due on the August 2012 Debenture as a component of current convertible debentures. December 2013 and April 2014 Convertible Debentures and Warrants On December 12, 2013, the Company issued 10% convertible debentures in the aggregate principal amount of $150,000 to two individual investors (the December 2013 Debentures) and on April 1, 2014, the Company issued a 10% convertible debenture in the principal amount of $75,000 to one individual investor (the April 2014 Debenture and together with the December 2013 Debentures, the Debentures). In connection with the issuance of the Debentures, the Company issued warrants (the Debenture Warrants) to purchase shares of the Companys common stock equal to 20% of the aggregate principal amount of the Debentures. The Debentures had a one year term with principal and interest on the December 2013 Debentures due December 12, 2014 and principal and interest on the April 2014 Debenture due April 1, 2015. The Debentures bear interest at a rate of 10% per annum. The Company separately accounted for the liability and equity components of the Debentures based upon the relative fair value of the liability and equity components on the date of issuance. As a result, the Company recorded a discount of $36,796 for the Debentures to account for the relative fair value attributable to the Debenture Warrants. The $36,796 debt discount was accreted as interest expense using the effective interest method over the respective one-year terms of the Debentures. On March 31, 2016, the Company issued 4,223,392 shares of common stock, at $0.065 per share, as full payment of the $225,000 of outstanding principal and $49,521 of accrued and unpaid interest due on the Debentures (see Note 8). Due to the reduction in the conversion price from $0.13 per share (as provided in the Debentures) to $0.065 per share, the Company recorded a loss on the inducement of the Debentures of $40,122 during the three and six months ended April 30, 2016. For the three and six months ended April 30, 2016, the Company recorded a total of $3,598 and $9,269, respectively, of interest expense related to the Debentures. For the three and six months ended April 30, 2015, the Company recorded a total of $7,456 ($1,970 accreted) and $18,895 ($7,738 accreted), respectively, of interest expense related to the Debentures. February 2015 Convertible Debenture and Warrant On February 12, 2015, the Company issued a 10% convertible debenture in the principal amount of $50,000 to an individual investor (the February 2015 Debenture). In connection with the issuance of the February 2015 Debenture, the Company issued a warrant (the February 2015 Debenture Warrant) to purchase shares of its common stock equal to 20% of the aggregate principal amount of the February 2015 Debenture. The February 2015 Debenture had a one-year term with principal and interest due February 12, 2016. The February 2015 Debenture bears interest at a rate of 10% per annum. The Company separately accounted for the liability and equity components of the February 2015 Debenture based upon the relative fair value of the liability and equity components on the date of issuance. As a result, the Company recorded a discount of $5,983 for the February 2015 Debenture to account for the relative fair value attributable to the February 2015 Debenture Warrant. The $5,983 debt discount was accreted as interest expense using the effective interest method over the one-year term of the February 2015 Debenture. On March 31, 2016, the Company issued 856,270 shares of common stock, at $0.065 per share, as full payment of the $50,000 of outstanding principal and $5,658 of accrued and unpaid interest due on the February 2015 Debenture (see Note 8). Due to the reduction in the conversion price from $0.13 per share (as provided in the February 2015 Debenture) to $0.065 per share, the Company recorded a loss on the inducement of the February 2015 Debenture of $8,135 during the three and six months ended April 30, 2016. For the three and six months ended April 30, 2016, the Company recorded a total of $1,020 ($197 accreted) and $3,788 ($1,705 accreted), respectively, of interest expense related to the February 2015 Debenture. For each of the three and six months ended April 30, 2015, the Company recorded a total of $2,660 ($1,605 accreted) of interest expense related to the February 2015 Debenture. September 2015 Convertible Debentures and Warrants On September 14, 2015, the Company issued 10% convertible debentures in the aggregate principal amount of $25,000 to three individual investors (the September 2015 Debentures). In connection with the issuance of the September 2015 Debentures, the Company issued warrants (the September 2015 Debenture Warrants) to purchase shares of its common stock equal to 20% of the aggregate principal amount of the September 2015 Debentures. The September 2015 Debentures had a one-year term with principal and interest due September 14, 2016. The September 2015 Debentures bear interest at a rate of 10% per annum. The Company separately accounted for the liability and equity components of the September 2015 Debentures based upon the relative fair value of the liability and equity components on the date of issuance. As a result, the Company recorded a discount of $4,022 for the September 2015 Debentures to account for the relative fair value attributable to the September 2015 Debenture Warrants. The $4,022 debt discount was accreted as interest expense using the effective interest method over the term of the September 2015 Debentures (September 14, 2015 through March 31, 2016, the date the September 2015 Debentures were converted into shares of common stock). On March 31, 2016, the Company issued 405,585 shares of common stock, at $0.065 per share as provided in the September 2015 Debentures, as full payment of the $25,000 of outstanding principal and $1,363 of accrued and unpaid interest due on the September 2015 Debentures (see Note 8). For the three and six months ended April 30, 2016, the Company recorded a total of $2,901 ($2,490 accreted) and $4,545 ($3,504 accreted), respectively, of interest expense related to the September 2015 Debentures. January 2016 Convertible Debenture and Warrant On January 4, 2016, the Company issued a 10% convertible debenture in the principal amount of $50,000 to an individual investor (the January 2016 Debenture). In connection with the issuance of the January 2016 Debenture, the Company issued a warrant (the January 2016 Debenture Warrant) to purchase shares of its common stock equal to 20% of the aggregate principal amount of the January 2016 Debenture. The January 2016 Debenture had a one-year term with principal and interest due January 4, 2017. The January 2016 Debenture bears interest at a rate of 10% per annum. The Company separately accounted for the liability and equity components of the January 2016 Debenture based upon the relative fair value of the liability and equity components on the date of issuance. As a result, the Company recorded a discount of $3,504 for the January 2016 Debenture to account for the relative fair value attributable to the January 2016 Debenture Warrant. The $3,504 debt discount was accreted as interest expense using the effective interest method over the term of the January 2016 Debenture (January 4, 2016 through March 31, 2016, the date the January 2016 Debenture was converted into shares of common stock). On March 31, 2016, the Company issued 787,566 shares of common stock, at $0.065 per share as provided in the January 2016 Debenture, as full payment of the $50,000 of outstanding principal and $1,192 of accrued and unpaid interest due on the January 2016 Debenture (see Note 8). For the three and six months ended April 30, 2016, the Company recorded a total of $4,043 ($3,235 accreted) and $4,696 ($3,504 accreted), respectively, of interest expense related to the January 2016 Debenture. |
Stock-Based Compensation
Stock-Based Compensation | 6 Months Ended |
Apr. 30, 2016 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Stock-Based Compensation | 6. Stock-Based Compensation The Company accounts for stock-based payments to employees in accordance with Accounting Standards Codification (ASC) 718, Stock Compensation (ASC 718). All stock-based payments to employees are grants of stock options that are recognized in the statement of operations based on their fair values at the date of grant. For each of the three and six months ended April 30, 2016 and 2015, the Company did not record any employee stock-based compensation expense. The Company accounts for stock-based payments to non-employees in accordance with ASC 718 and ASC 505-50, Equity-Based Payments to Non-Employees. For each of the three and six months ended April 30, 2016 and 2015, the Company did not record any non-employee stock-based compensation expense. |
Net Loss Per Common Share
Net Loss Per Common Share | 6 Months Ended |
Apr. 30, 2016 | |
Earnings Per Share [Abstract] | |
Net Loss Per Common Share | 7. Net Loss Per Common Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive. The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method. As of April 30, 2016, diluted net loss per share did not include the effect of 193,332 shares of common stock issuable upon the exercise of outstanding options, 903,846 shares of common stock issuable upon the exercise of outstanding warrants and 593,750 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive. As of April 30, 2015, diluted net loss per share did not include the effect of 203,332 shares of common stock issuable upon the exercise of outstanding options, 673,077 shares of common stock issuable upon the exercise of outstanding warrants and 2,782,051 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive. |
Stockholders' Equity
Stockholders' Equity | 6 Months Ended |
Apr. 30, 2016 | |
Equity [Abstract] | |
Stockholders' Equity | 8. Stockholders Equity Issuance of Common Stock as Payment of Principal and Interest on Convertible Debentures On March 31, 2016, the Company issued 856,934 shares of common stock as full payment of $175,000 of outstanding principal due on the February 2007 Debentures and $34,302 of accrued and unpaid interest for the period commencing February 1, 2014 through March 31, 2016 (January 31, 2016 for the February 2007 Debenture that was not converted into shares of common stock on March 31, 2016) (see Note 5). On March 31, 2016, the Company issued 128,205 shares of common stock to the May 2011 Debenture holder in satisfaction of $16,000 of interest due for the period commencing May 20, 2013 through May 19, 2015 (see Note 5). On March 31, 2016, the Company issued 161,538 shares of common stock to the August 2012 Debenture holder in satisfaction of $16,000 of interest due for the period commencing August 15, 2013 through August 14, 2015 (see Note 5). On March 31, 2016, the Company issued 4,223,392 shares of common stock as full payment of the $225,000 of outstanding principal and $49,521 of accrued and unpaid interest due on the Debentures (see Note 5). On March 31, 2016, the Company issued 856,270 shares of common stock as full payment of the $50,000 of outstanding principal and $5,658 of accrued and unpaid interest due on the February 2015 Debenture (see Note 5). On March 31, 2016, the Company issued 405,585 shares of common stock as full payment of the $25,000 of outstanding principal and $1,363 of accrued and unpaid interest due on the September 2015 Debentures (see Note 5). On March 31, 2016, the Company issued 787,566 shares of common stock as full payment of the $50,000 of outstanding principal and $1,192 of accrued and unpaid interest due on the January 2016 Debenture (see Note 5). Issuance of Common Stock as Payment of Accounts Payable Related Party On April 30, 2016, the Company issued to Century Capital 7,027,140 shares of common stock as payment of $135,000 of rent and $36,899 of expenses due under the Sublease Agreement for the period commencing February 1, 2014 through April 30, 2016 and $284,865 of other expenses due to Century Capital for the period commencing September 1, 2013 through April 30, 2016 (see Note 3). Stock Option Plans The Company currently has two stock option plans in place: the 2002 Equity Incentive Plan and the 2007 Equity Incentive Plan (collectively, the Equity Incentive Plans). The 2002 Equity Incentive Plan was approved by the stockholders on July 5, 2002. The aggregate number of shares of common stock which could have been awarded under the 2002 Equity Incentive Plan was 200,000. As of April 30, 2016, options to purchase 110,000 shares of the Companys common stock were outstanding under the 2002 Equity Incentive Plan. As a result of the adoption of the Companys 2007 Equity Incentive Plan, no further awards are permitted under the 2002 Equity Incentive Plan. On May 31, 2007, the stockholders approved the Companys 2007 Equity Incentive Plan. The original aggregate number of shares of common stock which could be awarded under the 2007 Equity Incentive Plan was 300,000 shares, subject to adjustment as provided in the 2007 Equity Incentive Plan. Effective December 27, 2013, as permitted under the 2007 Equity Incentive Plan, the Companys board of directors increased the number of shares of common stock that could be awarded under the 2007 Equity Incentive Plan to 814,408 shares. As of April 30, 2016, options to purchase 83,332 shares of the Companys common stock were outstanding under the 2007 Equity Incentive Plan and up to 731,076 shares of the Companys common stock remain available for awards under the 2007 Equity Incentive Plan. Stock option awards under the Equity Incentive Plans were granted at prices as determined by the Companys compensation committee, but such prices were not less than the fair market value of the Company's common stock on the date of grant. Stock options granted and outstanding include only non-qualified stock options that vested over a period of up to five years and have a maximum term of ten years from the date of grant. A summary of stock option transactions for employees and directors under the Equity Incentive Plans during the six months ended April 30, 2016 is as follows: Stock Option Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at October 31, 2015 203,332 $ 1.70 $ Granted during the period Exercised during the period Expired during the period (10,000 ) $ 0.80 Outstanding at April 30, 2016 193,332 $ 1.74 $ Exercisable at April 30, 2016 193,332 $ 1.74 $ Exercisable at October 31, 2015 203,332 $ 1.70 $ Information with respect to stock options outstanding and stock options exercisable as of April 30, 2016 that were granted to employees is as follows: Stock Options Outstanding Stock Options Exercisable Exercise Price Number of Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) Number of Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) $ 1.40 83,332 $ 1.40 2.4 83,332 $ 1.40 2.4 $ 2.00 110,000 $ 2.00 0.8 110,000 $ 2.00 0.8 193,332 $ 1.74 1.4 193,332 $ 1.74 1.4 Warrant to Purchase Common Stock A summary of warrant transactions during the six months ended April 30, 2016 is as follows: Warrant Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at October 31, 2015 750,000 $ 0.12 $ Issued during the period 153,846 $ 0.07 Exercised during the period Expired during the period Outstanding at April 30, 2016 903,846 $ 0.11 $ Exercisable at April 30, 2016 673,077 $ 0.13 $ Exercisable at October 31, 2015 596,154 $ 0.13 $ As of April 30, 2016, the weighted average remaining contractual life for warrants outstanding was 1.8 years and for warrants exercisable was 1.6 years. |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 6 Months Ended |
Apr. 30, 2016 | |
Warrant [Member] | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | |
Schedule of Stock Option Activity | A summary of warrant transactions during the six months ended April 30, 2016 is as follows: Warrant Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at October 31, 2015 750,000 $ 0.12 $ Issued during the period 153,846 $ 0.07 Exercised during the period Expired during the period Outstanding at April 30, 2016 903,846 $ 0.11 $ Exercisable at April 30, 2016 673,077 $ 0.13 $ Exercisable at October 31, 2015 596,154 $ 0.13 $ |
Stock Option [Member] | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | |
Schedule of Stock Option Activity | A summary of stock option transactions for employees and directors under the Equity Incentive Plans during the six months ended April 30, 2016 is as follows: Stock Option Shares Weighted Average Exercise Price Per Common Share Aggregate Intrinsic Value Outstanding at October 31, 2015 203,332 $ 1.70 $ Granted during the period Exercised during the period Expired during the period (10,000 ) $ 0.80 Outstanding at April 30, 2016 193,332 $ 1.74 $ Exercisable at April 30, 2016 193,332 $ 1.74 $ Exercisable at October 31, 2015 203,332 $ 1.70 $ |
Schedule of Stock Options Outstanding and Stock Options Exercisable | Information with respect to stock options outstanding and stock options exercisable as of April 30, 2016 that were granted to employees is as follows: Stock Options Outstanding Stock Options Exercisable Exercise Price Number of Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) Number of Options Weighted Average Exercise Price Per Common Share Weighted Average Remaining Contractual Life (Years) $ 1.40 83,332 $ 1.40 2.4 83,332 $ 1.40 2.4 $ 2.00 110,000 $ 2.00 0.8 110,000 $ 2.00 0.8 193,332 $ 1.74 1.4 193,332 $ 1.74 1.4 |
Basis of Presentation (Details
Basis of Presentation (Details Narrative) - USD ($) | Apr. 30, 2016 | Oct. 31, 2015 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Working capital deficiency | $ 335,700 | |
Accumulated deficit | 24,580,214 | $ 24,448,728 |
Principal payment due on convertible debenture | $ 25,000 |
Amended and Restated SCMS Lic17
Amended and Restated SCMS License Agreement (Details Narrative) - Donald D. Hickey [Member] - USD ($) | Feb. 14, 2011 | Apr. 30, 2016 | Jan. 22, 2016 |
SCMS License Agreement [Member] | |||
Cash payment to related party | $ 105,000 | ||
SCMS License Agreement [Member] | After Closing Any Single Financing [Member] | |||
Cash payment to related party | 50,000 | ||
SCMS License Agreement [Member] | Six Month Period [Member] | |||
Maximum closing single financing amount | 3,000,000 | ||
SCMS License Agreement [Member] | After First Commercial Sale of Licensed Technology [Member] | |||
Cash payment to related party | $ 55,000 | ||
License Termination Agreement [Member] | |||
Cash payment to related party | $ 105,000 | ||
Termination of license agreement | $ 105,000 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) | 3 Months Ended | 6 Months Ended | |||
Apr. 30, 2016USD ($) | Apr. 30, 2015USD ($) | Apr. 30, 2016USD ($)shares | Apr. 30, 2015USD ($) | Feb. 01, 2007ft² | |
Sublease agreement expenses | $ 16,281 | $ 17,073 | $ 38,235 | $ 34,693 | |
Number of shares issued | shares | 7,027,140 | ||||
Century Capital Associates LLC [Member] | |||||
Area of office space | ft² | 2,000 | ||||
Notice period to terminate sublease agreement | 60 days | ||||
Monthly rental fee | $ 5,000 | ||||
Sublease agreement expenses | 36,899 | ||||
Rent due under the Sublease Agreement | 135,000 | ||||
Other expenses included in accounts payable - related party | $ 284,865 | $ 284,865 |
Note Payable (Details Narrative
Note Payable (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Apr. 30, 2016 | Apr. 30, 2015 | Apr. 30, 2016 | Apr. 30, 2015 | |
Gain on settlement of note payable | $ 105,000 | |||
Donald D. Hickey [Member] | License Agreement [Member] | ||||
Cash payment to related party | $ 105,000 | 105,000 | ||
Donald D. Hickey [Member] | License Termination Agreement [Member] | ||||
Payment to related party | $ 105,000 |
Convertible Debentures (Details
Convertible Debentures (Details Narrative) - USD ($) | Mar. 31, 2016 | Jan. 04, 2016 | Sep. 14, 2015 | Feb. 12, 2015 | Dec. 12, 2013 | Aug. 15, 2012 | Jan. 11, 2012 | May 20, 2011 | Feb. 08, 2007 | Apr. 30, 2016 | Apr. 30, 2015 | Apr. 30, 2016 | Apr. 30, 2015 | Oct. 31, 2015 |
Debt instruments principal amount | $ 25,000 | $ 25,000 | ||||||||||||
Convertible debt carrying value net | 225,000 | 225,000 | $ 694,791 | |||||||||||
Loss on conversion of convertible debt | (48,257) | (48,257) | ||||||||||||
January 2016 Debenture Divided [Member] | ||||||||||||||
Debt instruments conversion into shares value | $ 50,000 | |||||||||||||
Debt instruments conversion into share | 787,566 | |||||||||||||
Accrued interest | $ 1,192 | |||||||||||||
Interest expense on debt | 4,043 | 4,696 | ||||||||||||
Debt discount | $ 3,504 | |||||||||||||
Accreted interest expense | 3,504 | 3,235 | 3,504 | |||||||||||
Conversion price per share | $ 0.065 | |||||||||||||
February 2007 Debentures [Member] | ||||||||||||||
Debt instruments principal amount | 25,000 | 25,000 | ||||||||||||
Debt instruments conversion into shares value | $ 175,000 | $ 50,000 | ||||||||||||
Debt instruments conversion into share | 856,934 | 50,000 | ||||||||||||
Accrued interest | $ 34,302 | |||||||||||||
Interest expense on debt | 2,793 | $ 3,902 | 6,826 | $ 7,935 | ||||||||||
Interest payable | 493 | 493 | ||||||||||||
Convertible debt carrying value net | 25,000 | 25,000 | ||||||||||||
February 2007 Debentures [Member] | Individual Investors [Member] | ||||||||||||||
Debt instruments principal amount | $ 250,000 | |||||||||||||
Debentures bear interest at rate | 8.00% | |||||||||||||
Debt maturity date | Jan. 31, 2010 | |||||||||||||
Debt initially extended date | Jan. 31, 2012 | |||||||||||||
Debt maturity term | 3 years | |||||||||||||
May 2011 Convertible Debenture [Member] | ||||||||||||||
Debt instruments conversion into share | 128,205 | |||||||||||||
Interest expense on debt | 1,973 | 1,951 | 3,990 | 3,968 | ||||||||||
Interest payable | $ 16,000 | 7,614 | 7,614 | |||||||||||
Convertible debt carrying value net | 100,000 | 100,000 | ||||||||||||
May 2011 Convertible Debenture [Member] | Institutional Investor [Member] | ||||||||||||||
Debt instruments principal amount | $ 100,000 | |||||||||||||
Debentures bear interest at rate | 8.00% | |||||||||||||
Debt maturity date | May 20, 2014 | |||||||||||||
Debt initially extended date | May 20, 2015 | |||||||||||||
Debt instrument new maturity date | Mar. 31, 2017 | |||||||||||||
Debt maturity term | 3 years | |||||||||||||
August 2012 Convertible Debenture [Member] | ||||||||||||||
Debt instruments conversion into share | 161,538 | |||||||||||||
Interest expense on debt | 1,973 | 1,951 | 3,990 | 3,968 | ||||||||||
Interest payable | $ 16,000 | 5,794 | 5,794 | |||||||||||
Convertible debt carrying value net | 100,000 | 100,000 | ||||||||||||
August 2012 Convertible Debenture [Member] | Institutional Investor [Member] | ||||||||||||||
Debt instruments principal amount | $ 100,000 | |||||||||||||
Debentures bear interest at rate | 8.00% | |||||||||||||
Debt maturity date | Aug. 15, 2015 | |||||||||||||
Debt instrument new maturity date | Mar. 31, 2017 | |||||||||||||
Debt maturity term | 3 years | |||||||||||||
December 2013 Debentures [Member] | Two Individual Investors [Member] | ||||||||||||||
Debt instruments principal amount | $ 150,000 | |||||||||||||
Debentures bear interest at rate | 10.00% | |||||||||||||
Debt maturity date | Dec. 12, 2014 | |||||||||||||
Debt maturity term | 1 year | |||||||||||||
April 2014 Debentures [Member] | Two Individual Investors [Member] | ||||||||||||||
Debt instruments principal amount | $ 75,000 | |||||||||||||
Debentures bear interest at rate | 10.00% | |||||||||||||
Debt maturity date | Apr. 1, 2015 | |||||||||||||
December 2013 and April 2014 Convertible Debentures and Warrants [Member] | ||||||||||||||
Debt instruments conversion into shares value | $ 225,000 | |||||||||||||
Debt instruments conversion into share | 4,223,392 | |||||||||||||
Accrued interest | $ 49,521 | |||||||||||||
Interest expense on debt | 3,598 | 7,456 | 9,269 | 18,895 | ||||||||||
Percentage of common stock equal aggregate principal amount | 20.00% | |||||||||||||
Debt discount | $ 36,796 | |||||||||||||
Accreted interest expense | $ 36,796 | 1,970 | 7,738 | |||||||||||
Conversion price per share | $ 0.065 | |||||||||||||
Loss on conversion of convertible debt | $ 40,122 | $ 40,122 | ||||||||||||
December 2013 and April 2014 Convertible Debentures and Warrants [Member] | Minimum [Member] | ||||||||||||||
Conversion price per share | $ 0.13 | $ 0.13 | ||||||||||||
December 2013 and April 2014 Convertible Debentures and Warrants [Member] | Maximum [Member] | ||||||||||||||
Conversion price per share | $ 0.065 | $ 0.065 | ||||||||||||
February 2015 Convertible Debenture and Warrant [Member] | ||||||||||||||
Debt instruments conversion into shares value | $ 50,000 | |||||||||||||
Debt instruments conversion into share | 856,270 | |||||||||||||
Accrued interest | $ 5,658 | |||||||||||||
Interest expense on debt | $ 1,020 | 2,660 | $ 3,788 | 2,660 | ||||||||||
Debt discount | $ 5,983 | |||||||||||||
Accreted interest expense | 5,983 | 197 | $ 1,605 | 1,705 | $ 1,605 | |||||||||
Conversion price per share | $ 0.065 | |||||||||||||
Loss on conversion of convertible debt | 8,135 | 8,135 | ||||||||||||
February 2015 Convertible Debenture and Warrant [Member] | Minimum [Member] | ||||||||||||||
Conversion price per share | 0.13 | |||||||||||||
February 2015 Convertible Debenture and Warrant [Member] | Maximum [Member] | ||||||||||||||
Conversion price per share | $ 0.065 | |||||||||||||
February 2015 Convertible Debenture and Warrant [Member] | Individual Investors [Member] | ||||||||||||||
Debt instruments principal amount | $ 50,000 | |||||||||||||
Debentures bear interest at rate | 10.00% | |||||||||||||
Debt instrument new maturity date | Feb. 12, 2016 | |||||||||||||
Debt maturity term | 1 year | |||||||||||||
Percentage of common stock equal aggregate principal amount | 20.00% | |||||||||||||
September 2015 Convertible Debentures and Warrants [Member] | ||||||||||||||
Debt instruments conversion into shares value | $ 25,000 | |||||||||||||
Debt instruments conversion into share | 405,585 | |||||||||||||
Accrued interest | $ 1,363 | |||||||||||||
Interest expense on debt | 2,901 | 4,545 | ||||||||||||
Debt discount | $ 4,022 | |||||||||||||
Accreted interest expense | 4,022 | $ (2,490) | $ (3,504) | |||||||||||
Conversion price per share | $ 0.065 | |||||||||||||
September 2015 Convertible Debentures and Warrants [Member] | Three Individual Investors [Member] | ||||||||||||||
Debt instruments principal amount | $ 25,000 | |||||||||||||
Debentures bear interest at rate | 10.00% | |||||||||||||
Debt instrument new maturity date | Sep. 14, 2016 | |||||||||||||
Debt maturity term | 1 year | |||||||||||||
Percentage of common stock equal aggregate principal amount | 20.00% | |||||||||||||
January 2016 Debenture and Warrant [Member] | Individual Investors [Member] | ||||||||||||||
Debt instruments principal amount | $ 50,000 | |||||||||||||
Debentures bear interest at rate | 10.00% | |||||||||||||
Debt instrument new maturity date | Jan. 4, 2017 | |||||||||||||
Debt maturity term | 1 year | |||||||||||||
Percentage of common stock equal aggregate principal amount | 20.00% |
Net Loss Per Common Share (Deta
Net Loss Per Common Share (Details Narrative) - shares | 6 Months Ended | |
Apr. 30, 2016 | Apr. 30, 2015 | |
Stock Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive shares which were not included in computation of diluted per share | 193,332 | 203,332 |
Warrant [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive shares which were not included in computation of diluted per share | 903,846 | 673,077 |
Convertible Debt Securities [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive shares which were not included in computation of diluted per share | 593,750 | 2,782,051 |
Stockholders' Equity (Details N
Stockholders' Equity (Details Narrative) | Mar. 31, 2016USD ($)shares | Jan. 11, 2012USD ($)shares | Dec. 27, 2013shares | Apr. 30, 2016USD ($)shares | Apr. 30, 2015USD ($) | Apr. 30, 2016USD ($)StockOptionPlansshares | Apr. 30, 2015USD ($) | Oct. 31, 2015shares | May 31, 2007shares | Jul. 05, 2002shares |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Number of shares issued | shares | 7,027,140 | |||||||||
Sublease agreement expenses | $ 16,281 | $ 17,073 | $ 38,235 | $ 34,693 | ||||||
Number of stock option plans | StockOptionPlans | 2 | |||||||||
Warrant [Member] | ||||||||||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Stock option plan outstanding | shares | 903,846 | 903,846 | 750,000 | |||||||
Weighted average warrants outstanding contractual life | 1 year 9 months 18 days | |||||||||
Weighted average warrants exercisable contractual life | 1 year 7 months 6 days | |||||||||
Equity Incentive Plans [Member] | ||||||||||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Stock options vested over period | 5 years | |||||||||
Equity Incentive Plans [Member] | Maximum [Member] | ||||||||||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Stock options grant date term | 10 years | |||||||||
2002 Equity Incentive Plan [Member] | ||||||||||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Aggregate number of common stock shares awarded | shares | 200,000 | |||||||||
Stock option plan outstanding | shares | 110,000 | 110,000 | ||||||||
2007 Equity Incentive Plan [Member] | ||||||||||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Aggregate number of common stock shares awarded | shares | 300,000 | |||||||||
Stock option plan outstanding | shares | 83,332 | 83,332 | ||||||||
Increased in number of common stock shares awarded | shares | 814,408 | |||||||||
Common stock available for awards under equity incentive plan | shares | 731,076 | 731,076 | ||||||||
January 2016 Debenture Divided [Member] | ||||||||||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Debt instruments conversion into shares value | $ 50,000 | |||||||||
Debt instruments conversion into share | shares | 787,566 | |||||||||
Accrued interest | $ 1,192 | |||||||||
Century Capital Associates LLC [Member] | ||||||||||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Rent due under the Sublease Agreement | $ 135,000 | |||||||||
Sublease agreement expenses | 36,899 | |||||||||
Other expenses included in accounts payable - related party | $ 284,865 | 284,865 | ||||||||
February 2007 Debentures [Member] | ||||||||||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Debt instruments conversion into shares value | $ 175,000 | $ 50,000 | ||||||||
Debt instruments conversion into share | shares | 856,934 | 50,000 | ||||||||
Accrued interest | $ 34,302 | |||||||||
Interest payable | 493 | 493 | ||||||||
May 2011 Convertible Debenture [Member] | ||||||||||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Debt instruments conversion into share | shares | 128,205 | |||||||||
Interest payable | $ 16,000 | 7,614 | 7,614 | |||||||
August 2012 Convertible Debenture [Member] | ||||||||||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Debt instruments conversion into share | shares | 161,538 | |||||||||
Interest payable | $ 16,000 | $ 5,794 | $ 5,794 | |||||||
December 2013 and April 2014 Convertible Debentures and Warrants [Member] | ||||||||||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Debt instruments conversion into shares value | $ 225,000 | |||||||||
Debt instruments conversion into share | shares | 4,223,392 | |||||||||
Accrued interest | $ 49,521 | |||||||||
February 2015 Convertible Debenture and Warrant [Member] | ||||||||||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Debt instruments conversion into shares value | $ 50,000 | |||||||||
Debt instruments conversion into share | shares | 856,270 | |||||||||
Accrued interest | $ 5,658 | |||||||||
September 2015 Convertible Debentures and Warrants [Member] | ||||||||||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||||||||||
Debt instruments conversion into shares value | $ 25,000 | |||||||||
Debt instruments conversion into share | shares | 405,585 | |||||||||
Accrued interest | $ 1,363 |
Stockholders' Equity - Schedule
Stockholders' Equity - Schedule of Stock Option Activity (Details) | 6 Months Ended |
Apr. 30, 2016USD ($)$ / sharesshares | |
Warrant [Member] | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | |
Stock Option/Warrants Shares, Outstanding Beginning Balance | shares | 750,000 |
Stock Option/Warrants Shares, Granted/Issued during the period | shares | 153,846 |
Stock Option/Warrants Shares, Exercised during the period | shares | |
Stock Option/Warrants Shares, Expired during the period | shares | |
Stock Option/Warrants Shares, Outstanding Ending Balance | shares | 903,846 |
Stock Option/Warrants Shares, Exercisable at april 30, 2016 | shares | 673,077 |
Stock Option/Warrants Shares, Exercisable at October 31, 2015 | shares | 596,154 |
Weighted Average Exercise Price Per Common Share/Warrants, Outstanding Beginning Balance | $ / shares | $ 0.12 |
Weighted Average Exercise Price Per Common Share/Warrants, Granted/Issued during the period | $ / shares | $ 0.07 |
Weighted Average Exercise Price Per Common Share/Warrants, Exercised during the period | $ / shares | |
Weighted Average Exercise Price Per Common Share/Warrants, Expired during the period | $ / shares | |
Weighted Average Exercise Price Per Common Share/Warrants Outstanding Ending Balance | $ / shares | $ 0.11 |
Weighted Average Exercise Price Per Common Share, Exercisable at april 30, 2016 | $ / shares | 0.13 |
Weighted Average Exercise Price Per Common Share, Exercisable at October 31, 2015 | $ / shares | $ 0.13 |
Aggregate Intrinsic Value, Outstanding Stock Option/Warrants Beginning balance | $ | |
Aggregate Intrinsic Value Outstanding Stock Option/Warrants, Ending Balance | $ | |
Aggregate Intrinsic Value, Stock Option/Warrants, Exercisable at april 30, 2016 | $ | |
Aggregate Intrinsic Value, Stock Option/Warrants, Exercisable at October 31, 2015 | $ | |
Stock Option [Member] | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | |
Stock Option/Warrants Shares, Outstanding Beginning Balance | shares | 203,332 |
Stock Option/Warrants Shares, Granted/Issued during the period | shares | |
Stock Option/Warrants Shares, Exercised during the period | shares | |
Stock Option/Warrants Shares, Expired during the period | shares | (10,000) |
Stock Option/Warrants Shares, Outstanding Ending Balance | shares | 193,332 |
Stock Option/Warrants Shares, Exercisable at april 30, 2016 | shares | 193,332 |
Stock Option/Warrants Shares, Exercisable at October 31, 2015 | shares | 203,332 |
Weighted Average Exercise Price Per Common Share/Warrants, Outstanding Beginning Balance | $ / shares | $ 1.70 |
Weighted Average Exercise Price Per Common Share/Warrants, Granted/Issued during the period | $ / shares | |
Weighted Average Exercise Price Per Common Share/Warrants, Exercised during the period | $ / shares | |
Weighted Average Exercise Price Per Common Share/Warrants, Expired during the period | $ / shares | $ 0.80 |
Weighted Average Exercise Price Per Common Share/Warrants Outstanding Ending Balance | $ / shares | 1.74 |
Weighted Average Exercise Price Per Common Share, Exercisable at april 30, 2016 | $ / shares | 1.74 |
Weighted Average Exercise Price Per Common Share, Exercisable at October 31, 2015 | $ / shares | $ 1.70 |
Aggregate Intrinsic Value, Outstanding Stock Option/Warrants Beginning balance | $ | |
Aggregate Intrinsic Value Outstanding Stock Option/Warrants, Ending Balance | $ | |
Aggregate Intrinsic Value, Stock Option/Warrants, Exercisable at april 30, 2016 | $ | |
Aggregate Intrinsic Value, Stock Option/Warrants, Exercisable at October 31, 2015 | $ |
Stockholders' Equity - Schedu24
Stockholders' Equity - Schedule of Stock Options Outstanding and Stock Options Exercisable (Details) - Stock Option [Member] | 6 Months Ended |
Apr. 30, 2015$ / sharesshares | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | |
Number of Available Under Outstanding Stock | shares | 193,332 |
Weighted Average Exercise Price Per Common Share | $ 1.74 |
Weighted Average Remaining Contractual Life (Years) | 1 year 4 months 24 days |
Number of Shares Available for Purchase Under | shares | 193,332 |
Weighted Average Exercise Price Per Common Share | $ 1.74 |
Weighted Average Remaining Contractual Life (Years) | 1 year 4 months 24 days |
Exercise Price One [Member] | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | |
Exercise Price | $ 1.40 |
Number of Available Under Outstanding Stock | shares | 83,332 |
Weighted Average Exercise Price Per Common Share | $ 1.40 |
Weighted Average Remaining Contractual Life (Years) | 2 years 4 months 24 days |
Number of Shares Available for Purchase Under | shares | 83,332 |
Weighted Average Exercise Price Per Common Share | $ 1.40 |
Weighted Average Remaining Contractual Life (Years) | 2 years 4 months 24 days |
Exercise Price Two [Member] | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | |
Exercise Price | $ 2 |
Number of Available Under Outstanding Stock | shares | 110,000 |
Weighted Average Exercise Price Per Common Share | $ 2 |
Weighted Average Remaining Contractual Life (Years) | 9 months 18 days |
Number of Shares Available for Purchase Under | shares | 110,000 |
Weighted Average Exercise Price Per Common Share | $ 2 |
Weighted Average Remaining Contractual Life (Years) | 9 months 18 days |